Q-omics provides the consensus-scored MRPS10 profile across patient tissues and cancer cell-line models. MRPS10 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MRPS10 is differentially expressed in 15, with the highest sampling consensus in LUAD. Additionally, MRPS10 protein abundance shows 30,236 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, LUAD, and LSCC as cancer lineages where MRPS10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPS10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPS10 survival associations across molecular data types. MRPS10 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPS10 RNA expression–survival associations across cancer types. High MRPS10 expression shows unfavorable associations in ACC, KICH, PAAD, LIHC, SARC and CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MRPS10 RNA expression.
This table summarizes MRPS10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 14. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MRPS10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPS10 shows lower tumor expression in THCA and KICH and higher tumor expression in LUAD, LIHC, BRCA and BLCA. The LUAD box plot shows higher MRPS10 RNA expression in tumor versus normal tissue (log2 FC = +0.979, t-test p < 0.001).
This table shows molecular features associated with MRPS10 in patient tissues and cancer cell lines. In patient samples, MRPS10 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPS10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
